𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of levodopa-induced motor complications

✍ Scribed by Fabrizio Stocchi; Michele Tagliati; C. Warren Olanow

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
138 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (MAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place.

📜 SIMILAR VOLUMES

Levodopa-related motor complications—Phe
Levodopa-related motor complications—Phenomenology
✍ Susan H. Fox; Anthony E. Lang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Long term levodopa therapy in Parkinson's disease (PD) results in a range of problems. These include fluctuations in FD symptoms termed motor fluctuations, as well as non-motor symptoms, termed non-motor fluctuations. Here we review the phenomenology and methods of assessing these levodopa-related c

Glutamate release inhibition ineffective
Glutamate release inhibition ineffective in Levodopa-induced motor complications
✍ William Bara-Jimenez; Tzvetelina D. Dimitrova; Abdullah Sherzai; Murat Aksu; Tho 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3‐week, double‐blind, proof‐of‐concept study, riluzole (200

Changes of GABA receptors and dopamine t
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
✍ Frédéric Calon; Marc Morissette; Ali H. Rajput; Oleh Hornykiewicz; Paul J. Bédar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing‐off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β‐(4‐^125^I‐iodophenyl)tropane‐2β‐carboxylic acid isopropyl ester ([^125^I]RTI‐121) ‐specifi

Role of surgery in the treatment of moto
Role of surgery in the treatment of motor complications
✍ Leo Verhagen Metman; Shaun T. O'Leary 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

When medications no longer provide patients with Parkinson's disease a reasonable quality of life due to the presence of levodopa-associated motor fluctuations and dyskinesias, surgical treatment is often pursued. Numerous studies have examined the antiparkinsonian efficacy of procedures currently a